PACS stock forecast, quote, news & analysis
PACS Group Inc is a post-acute healthcare company mainly focused on delivering skilled nursing care through a portfolio of independently operated facilities... Show more
Why PACS Group (PACS) Stock Is Up +13.3% in the Last 30 Days
Key Takeaways
- PACS Group shares have climbed roughly 13.3% over the past 30 days, recovering sharply from early-October lows near $40 to trade around $47.72.
- The advance follows a larger pullback earlier in the quarter, leaving the stock up a more modest amount over the trailing three-month period despite elevated volatility.
- Aggressive acquisition execution — including the Eduro Healthcare portfolio and a 32-facility Florida expansion — has been a central driver of investor sentiment.
- Second-quarter results beat expectations and came with raised full-year 2026 revenue and adjusted EBITDA guidance.
- Ongoing federal investigations into billing practices and financial controls remain a key risk that investors continue to weigh.
PACS Group (PACS) Company Overview and Market Position
PACS Group, Inc. (NYSE: PACS) is a holding company and one of the largest post-acute healthcare platforms in the United States. Founded in 2013 and headquartered in the Salt Lake City, Utah area, the company invests in skilled nursing and senior living facilities, professionals, and ancillary services. Its independent subsidiaries operate hundreds of post-acute care communities across the country, serving tens of thousands of patients daily.
PACS operates through a "locally led, centrally supported" model. Individual facility administrators run day-to-day operations close to the patient, while its PACS Services division provides back-office functions such as accounting, compliance, payroll, human resources, legal, and risk management. This structure is designed to let care teams focus on clinical quality while capturing scale efficiencies across the platform. Investors follow the stock closely because of the company's rapid acquisition-driven growth, its leverage to an aging U.S. population, and its track record of improving occupancy and clinical acuity at acquired facilities.
PACS Group (PACS) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, PACS shares have advanced approximately 13.3%, moving from a closing level near $42.12 in mid-September to around $47.72. The move reflects a sharp rebound from the stock's early-October trough, when shares briefly traded near the $40 level.
The trailing three-month picture is more muted. From a mid-July closing price around $44.73, the stock is up roughly 6-7% through the latest session — but that gain masks considerable swings. Shares climbed toward the upper $40s in mid-August, retreated through September, and then staged the current recovery. The result is a volatile quarter in which the stock has round-tripped between roughly $40 and $48 before settling near the upper end of that range.
What Drove PACS Stock Price in the Last 30 Days
The recent advance has been powered by a combination of deal momentum, raised guidance, and favorable analyst commentary. In early September, PACS announced an agreement to acquire the operations of 32 skilled nursing facilities across Florida — totaling more than 4,000 licensed beds — leased from real estate investment trust Omega Healthcare Investors (OHI). The transaction significantly deepens the company's footprint in the South and reinforces its broader expansion strategy.
The move builds on the company's largest recent transaction: the acquisition of 34 facilities from Eduro Healthcare, announced in late June. The first 20 Texas facilities closed on August 1, 2026, with the remainder expected to close in tranches. Earlier in the quarter, PACS reported second-quarter results that exceeded consensus estimates, and management raised full-year 2026 revenue guidance to $5.75 billion–$5.85 billion and adjusted EBITDA guidance to $640 million–$660 million.
Several sell-side firms also lifted price targets following the results and the Florida announcement, citing improved visibility into acquisition-driven growth. These factors, combined with a rebound from oversold levels, supported the stock's recovery from its early-October low.
What Drove PACS Stock Performance Over the Last Quarter
Across the full quarter, PACS shares have been shaped by a larger narrative of rapid expansion weighed against persistent regulatory overhang. The company continued to execute on its growth playbook, closing tranches of the Eduro acquisition and unveiling the Florida deal, while reporting strong same-store metrics — including a 5.8% increase in same-store skilled nursing revenue and a 150-basis-point improvement in same-store occupancy.
At the same time, the stock's mid-quarter pullback reflected broader caution. PACS remains under investigation by the U.S. Department of Justice regarding Medicare claims and by the SEC concerning reporting and internal controls, following an earlier restatement of 2024 results. Management has said the internal investigation concluded and that it is cooperating with authorities. These unresolved matters, alongside periodic insider selling reported in SEC filings, contributed to choppiness even as the operational story improved. The net result has been a quarter defined more by volatility than by a clean directional trend.
Trending AI Robots
For traders seeking a systematic approach to stocks like PACS, Tickeron's Trending AI Robots page offers a curated look at AI-driven trading strategies. Tickeron hosts hundreds of AI trading bots that collectively trade thousands of tickers, but only top-performing and most relevant bots are featured in this section. These bots vary widely in strategy, trading timeframe, and performance metrics, allowing users to explore approaches ranging from short-term momentum to longer-horizon positioning. Reviewing the selection can provide useful perspective on how automated systems are currently reading market conditions.
PACS Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, the key catalysts for PACS center on deal execution, guidance, and regulatory resolution. Investors will monitor the completion of the remaining Eduro tranches and the Florida transaction, along with any additional acquisition announcements, given the company's emphasis on disciplined expansion and its large pipeline of opportunities.
Fundamentals will also be in focus, including occupancy trends, skilled-mix improvement, labor costs, and reimbursement rates. CMS raised Medicare rates for fiscal year 2027, and PACS has highlighted favorable Medicaid rate dynamics, but margin expansion will still depend heavily on operational efficiency. Finally, progress — or setbacks — in the ongoing DOJ and SEC investigations, changes in insider selling activity, and any updates on internal-control remediation will remain important sentiment drivers. As always, these factors should be evaluated in the context of the company's leverage to demographic tailwinds and the competitive dynamics of the skilled nursing sector.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
PACS in upward trend: price rose above 50-day moving average on October 12, 2026
PACS moved above its 50-day moving average on October 12, 2026 date and that indicates a change from a downward trend to an upward trend. In 18 of 20 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 02, 2026. You may want to consider a long position or call options on PACS as a result. In 23 of 37 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 62%.
The Moving Average Convergence Divergence (MACD) for PACS just turned positive on October 02, 2026. Looking at past instances where PACS's MACD turned positive, the stock continued to rise in 10 of 15 cases over the following month. The odds of a continued upward trend are 67%.
The 10-day moving average for PACS crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 6 of 8 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 75%.
Following a +7.59% 3-day Advance, the price is estimated to grow further. Considering data from situations where PACS advanced for three days, in 105 of 130 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
Bearish Trend Analysis
The 10-day RSI Indicator for PACS moved out of overbought territory on October 19, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 20 similar instances where the indicator moved out of overbought territory. In 19 of the 20 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 11 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PACS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.
PACS broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for PACS entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. PACS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 35 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 82 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.668) is normal, around the industry mean (204.137). P/E Ratio (27.186) is within average values for comparable stocks, (19.387). Projected Growth (PEG Ratio) (1.085) is also within normal values, averaging (2.498). Dividend Yield (0.000) settles around the average of (0.095) among similar stocks. P/S Ratio (1.209) is also within normal values, averaging (2.688).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PACS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 87, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry HospitalNursingManagement